Vice versa, de-escalation of the current DCIS treatment by omitting radiotherapy could be considered in ER-positive, HER2-negative low grade DCIS [12], resulting in more personalized treatment. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.